Loading data for TXG — first visit, this takes a few seconds.

10x Genomics, Inc. (TXG)

NasdaqGS: TXG · Real-Time Price · USD

61.65

+1.67 (2.78%)

At close: Sep 02, 2026, 3:59 PM

61.58

-0.11%

After-hours: 7:36 PM

Alert

The price, the headline numbers and the latest news, in one place.

2.78% (1D)

Bid	44.21
Market Cap	8.03B
Revenue (ttm)	617M
Net Income (ttm)	-75.1M
	2.04
	-0.59
	n/a
	303.2
P/B (ttm)	9.77
P/S (ttm)	13.02
Earnings Date	Nov 5, 2026

Ask	76.28
Volume	1,604,525
Avg. Volume (20D)	3,232,530
Open	60.24
Previous Close	59.98
Day's Range	59.42 - 63.49
52-Week Range	11.16 - 66.94
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About TXG

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instr...

[Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Sep 12, 2019

Employees 1,178

Stock Exchange NasdaqGS

Ticker Symbol TXG

Website https://www.10xgenomics.com

Full Company Profile

Financial Performance

In 2025, 10x Genomics's revenue was 642.82M, an increase of 5.25% compared to the previous year's 610.79M. Earnings were -43.54M, a decrease of -76.16%.

Financial Statements

Earnings Surprise

10x Genomics has released their quarterly earnings on Aug 6, 2026:

Revenue of $151.04M misses estimates by $0, with -12.65% YoY decline.
EPS of 0.03 exceeds estimates by 0.05, with -93.75% YoY decline.

Next Earnings Release

10x Genomics, Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 day ago · MT Newswires

10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC Says

10x Genomics (TXG) is offering a compelling product cycle but its two franchises are pulling in oppo

2 days ago · Zacks

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

5 days ago · MT Newswires

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Str

1 week ago · StockStory

3 Small-Cap Stocks with Open Questions

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside ri...

2 weeks ago · Insider Monkey

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

On August 6, 10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara. Strip that out and revenue grew just 3% year-over-year...

Page 1 of 2

10x Genomics, Inc. (TXG)